Investigating a new treatment for aggressive breast cancer using targeted antibody therapy
Preclinical efficacy of GPR56 antibody-drug conjugates and combination therapies for triple-negative breast cancer
This study is exploring a new treatment for triple-negative breast cancer that uses special drugs designed to target cancer cells directly, which could help improve results and lessen side effects for patients.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Texas Hlth Sci Ctr Houston NIH-funded |
| Lab location | 1 site (Houston, United States) |
| Project ID | NIH-11112706 on NIH RePORTER |
What this research studies
This research focuses on developing a new type of treatment for triple-negative breast cancer (TNBC), which is known for its aggressive nature and poor prognosis. The approach involves using antibody-drug conjugates (ADCs) that combine antibodies specifically targeting cancer cells with potent drugs to deliver treatment directly to tumors while minimizing damage to healthy tissues. The study aims to identify GPR56, a receptor found on TNBC cells, as a target for these ADCs, potentially improving treatment outcomes and reducing side effects for patients. By testing these therapies in preclinical models, the research seeks to establish their effectiveness and safety before moving to clinical trials.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with triple-negative breast cancer, particularly those who have not responded well to existing therapies.
Not a fit: Patients with non-triple-negative breast cancer or those who are not eligible for experimental therapies may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective and safer treatment options for patients with triple-negative breast cancer.
How similar studies have performed: Other research has shown promising results with similar antibody-drug conjugate approaches in treating various cancers, indicating potential for success in this novel application.
Where this research is happening
Houston, United States
- University of Texas Hlth Sci Ctr Houston — Houston, United States (Active)
Researchers
- Principal investigator: Carmon, Kendra S. — University of Texas Hlth Sci Ctr Houston
- Study coordinator: Carmon, Kendra S.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.